-
21
Blood Transcriptional Signatures for Disease Progression in a Rat Model of Osteoarthritis
Published 2017-01-01Get full text
Article -
22
-
23
-
24
-
25
-
26
Henoch–Schönlein Purpura (IgA Vasculitis) in Association with Thyrotoxicosis
Published 2021-01-01Get full text
Article -
27
-
28
-
29
-
30
-
31
-
32
Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk
Published 2025-01-01“…Louis, Missouri, USA; 8Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, Clinical Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA; 10Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 11Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA, USA; 12Department of Psychiatry, Harvard University School of Medicine, Cambridge, MA, USA; 13Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 14Brain & Behavior Laboratory, Department of Psychology, Curry College, Milton, Massachusetts, USA; 15Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX, USACorrespondence: Rajendra D Badgaiyan; Kenneth Blum, Email badgaiyan@gmail.com; drd2gene@gmail.com…”
Get full text
Article -
33
Hybrid probe combining MicroLED and neural electrode for precise neural modulation and multi-site recording
Published 2025-01-01Get full text
Article -
34
-
35
Using a Two-Steps Clustering and PCA Analysis for Stratified Chronic Non-Cancer Pain Care: A Retrospective Cross-Sectional Study
Published 2025-02-01“…Ana M Peiró,1,2 Jordi Barrachina,1 Mónica Escorial,1 Isidro Aguado,1 César Margarit,1,3 Anna Grimby-Ekman4 1Neuropharmacology Applied to Pain (NED), Clinical Pharmacology Unit, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, 03010, Spain; 2Institute of Bioengineering, University Miguel Hernández, Elche, 03202, Spain; 3Pain Unit, Alicante Department of Health -General Hospital, Alicante, 03010, Spain; 4School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenCorrespondence: Ana M Peiró, Alicante Institute for Health and Biomedical Research (ISABIAL), Hospital General Universitario Doctor Balmis, c/Pintor Baeza, 12, Alicante, 03010, Spain, Email apeiro@umh.esPurpose: Given the number of people who suffer from chronic pain and the impact on healthcare resources, it is imperative that the people with pain receive an appropriate matched treatment due and stratified care. …”
Get full text
Article -
36
-
37
-
38
Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generali...
Published 2025-02-01“…., Del Mar, CA, USA; 7Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 8Division of Addiction Research & Education, Center for Sports, Exercise and Mental Health, Western University Health Sciences, Pomona, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory On Addictions (BNNLA), Research Institute On Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; 10Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel; 11Stanford University, Psychiatric /Public Mental Health & Population Sciences Palo Alto, Stanford, CA, USA; 12Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá D.C., Colombia*These authors contributed equally to this workCorrespondence: Kenneth Blum, Email drd2gene@gmail.comAbstract: Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) are prevalent comorbidities related to a greater likelihood of poor treatment outcomes and prolonged treatment for Reward Deficiency Syndrome (RDS) behaviors. …”
Get full text
Article -
39
-
40
Deciphering In Vitro and In Vivo Pharmacological Properties of Seed and Fruit Extracts of Flacourtia jangomas (Lour.) Raeusch
Published 2024-01-01“…In both in vivo analgesic tests, SFJC demonstrated substantial (p<0.01) pain inhibition percentages (tail immersion: 49.46%; acetic acid writhing: 66.43%) at a dose of 600 mg/kg. During neuropharmacological screening, all extracts significantly (p<0.01; p<0.05) and dose-dependently decreased the mice’s locomotion activity and motor balance. …”
Get full text
Article